Proactively manage your pharmacy inventory
Find generic entry opportunities
Drug patents …
… from Kazakhstan to Kalamazoo
Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Manage your formulary budget
Anticipate generic drug launch
Flat-rate pricing for predictable budgeting
Short-term plans for project- or client-based billing
|Title:||Crystalline form of 4-[5-methyl-3-phenylisoxazol-4-yl] benzenesulfonamide|
|Abstract:||A stable crystalline form of 4-[5-methyl-3-phenylisoxazol-4-yl]benzenesulfonamide is described. This crystal structure, designated Form B, is more stable, has favorable handling properties and is characterized by its melting point, x-ray and other physical characterizations.|
|Inventor(s):||Talley; John J (Brentwood, MO), Medich; John R (Gurnee, IL), McLaughlin; Kathleen T (Arlington Heights, IL), Gaud; Henry T (Evanston, IL), Yonan; Edward E (Carol Stream, IL)|
|Assignee:||G. D. Searle & Co. (Skokie, IL)|
Patent Claim Types:|
see list of patent claims
Back Citations: 5th percentile
Forward Citations: 0th percentile
|Patent Number||Expiration Date|
|7,135,489||November 14, 2010|
|Country||Document Number||Estimated Expiration||Supplementary Protection Certificate||SPC Country||SPC Expiration|
| This preview shows a limited data set|
Subscribe for full access, or try a Trial
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.